SCHEMBL14769660

SCHEMBL14769660

COc1cc(C(=O)/C=C/c2ccccc2)cc(C)c1C

nearest known ligand 0.72

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TNFRSF1A P19438 4/20 0.72
ABCG2 Q9UNQ0 2/20 0.61
ABCB1 P08183 2/20 0.60
MAPT P10636 3/20 0.57
MAOB P27338 2/20 0.57
MEN1 O00255 2/20 0.57
KMT2A Q03164 2/20 0.57
CYP1B1 Q16678 2/20 0.57
ALDH1A1 P00352 1/20 0.57
HSPD1 P10809 1/20 0.57
HSPE1 P61604 1/20 0.57
NPC1 O15118 1/20 0.54
RAB9A P51151 1/20 0.54
NPSR1 Q6W5P4 1/20 0.54
BCHE P06276 2/20 0.54
CYP3A4 P08684 1/20 0.54
NFKB1 P19838 1/20 0.54
NFKB2 Q00653 1/20 0.54
RELA Q04206 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15807369 0.85 NPC1 (0.56) TNFRSF1AABCG2ABCB1MAPTMAOB
SCHEMBL15807343 0.84 TNFRSF1A (0.79) TNFRSF1AABCG2ABCB1MAPTMAOB
SCHEMBL12484514 0.84 TNFRSF1A (1.00) TNFRSF1AABCG2ABCB1
SCHEMBL12484518 0.84 TNFRSF1A (1.00) TNFRSF1AABCG2ABCB1
SCHEMBL15807324 0.83 ABCG2 (0.58) TNFRSF1AABCG2MAPTMAOBMEN1
SCHEMBL15807321 0.83 CXCL12 (0.62) TNFRSF1AABCG2ABCB1MAOBCYP1B1
SCHEMBL15807368 0.83 MAOB (0.66) TNFRSF1AABCG2ABCB1MAOB
SCHEMBL15807327 0.83 P4HB (0.71) TNFRSF1AABCG2ABCB1MAOB
SCHEMBL15460412 0.83 TUBB1 (0.74) ABCG2MAPTMEN1KMT2ACYP1B1
SCHEMBL15807322 0.82 KRAS (0.76) ABCG2MAPTMAOBMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8889874-B2 Imidazolone-chalcone derivatives as potential anticancer agent and process for the preparation thereof COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2014-11-18 US disclosed
US-20140171503-A1 NUCLEAR RECEPTOR MODULATORS AND THEIR USE FOR THE TREATMENT AND PREVENTION OF CANCER HUMAN SERVICES (US) 2014-06-19 US disclosed
US-20130066081-A1 IMIDAZOLONE-CHALCONE DERIVATIVES AS POTENTIAL ANTICANCER AGENT AND PROCESS FOR THE PREPARATION THEREOF COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2013-03-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130066081-A1 IMIDAZOLONE-CHALCONE DERIVATIVES AS POTENTIAL ANTICANCER AGENT AND PROCESS FOR THE PREPARATION THEREOF SIK1, SIK2, SIK3 TNFRSF1A 2778/4885ABCG2 390/4885ABCB1 571/4885
US-20140171503-A1 NUCLEAR RECEPTOR MODULATORS AND THEIR USE FOR THE TREATMENT AND PREVENTION OF CANCER AR, NCOA1, NR5A1 TNFRSF1A 777/4885ABCG2 742/4885ABCB1 934/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.